Physician

Joseph R Mace, MD

According to 2025 Medicare claims, Joseph Mace, MD (NPI: 1083605240) practices medical oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33707-4505.

Mace's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 488 traditional Medicare patients, billed 163,641 HCPCS/CPT codes, and received $1,859,336 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,417 prescription claims across 234 beneficiaries totaling $1,605,759 in drug costs, led by Xtandi (Enzalutamide). DME data shows 28 claims. Open Payments data shows 164 records totaling $29,267. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $804,995 to $1,605,759. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	717	198,627	$1,792,792
2016	614	146,635	$1,533,607
2017	634	203,574	$1,922,910
2018	582	178,215	$2,209,250
2019	642	185,513	$2,302,138
2020	461	196,244	$2,055,591
2021	415	161,201	$1,971,658
2022	485	172,563	$2,099,007
2023	474	223,614	$1,668,073
2024	488	163,641	$1,859,336

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	159	830	$804,995
2016	151	850	$927,777
2017	146	764	$788,302
2018	129	750	$911,929
2019	130	635	$481,475
2020	121	781	$878,515
2021	179	965	$906,795
2022	204	1,213	$1,483,758
2023	212	1,316	$1,281,523
2024	234	1,417	$1,605,759

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	26	$17,528
2017	N/R	N/R	N/R
2018	N/R	39	$5,073
2019	N/R	29	$2,218
2020	N/R	N/R	N/R
2021	N/R	14	$2,016
2022	N/R	11	$670
2023	N/R	N/R	N/R
2024	N/R	28	$622

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	224	533	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	227	456	$13
96372	Injection of drug or substance under skin or into muscle	136	627	$11
36415	Insertion of needle into vein for collection of blood sample	374	1,515	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	381	1,587	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	19	570	$267,106
Lumakras	Sotorasib	12	360	$253,658
Brukinsa	Zanubrutinib	21	630	$230,537
Imbruvica	Ibrutinib	13	364	$212,751
Lynparza	Olaparib	12	360	$202,483

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$459
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	130	$2,891	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	34	$26,377	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph R. Mace, MD?

Tedicare shows public-source Medicare data for Joseph R. Mace, MD (NPI 1083605240), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph R. Mace, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph R. Mace, MD?

Joseph R. Mace, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Joseph R. Mace, MD have Open Payments data?

Joseph R. Mace, MD has 164 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.